2013-08-14 13:54:15 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Hemispherx BioPharma, Inc (HEB) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Hemispherx BioPharma, Inc (HEB). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Hemispherx BioPharma, Inc investor.
Report Summary: Hemispherx BioPharma, Inc is a low quality company with a neutral outlook. Hemispherx BioPharma, Inc has medium business growth and is run by inefficient management. The trend in Hemispherx BioPharma, Inc fair value exchange rate against its closest rated-competitor, Cyclacel Pharmaceuticals Inc, has been appreciating over the past 2 weeks. When compared to its closest competitor, Hemispherx BioPharma, Inc shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three
components - business, management and price, performing an in-depth analysis of Hemispherx BioPharma, Inc for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.